Does Dr. SULAIMAN ALHUMAID have financial conflicts of interest?

Dr. SULAIMAN ALHUMAID (MD) has received a total of $1,256 in pharmaceutical and medical device industry funding between 2021 and 2025. This includes $1,256 in personal promotional payouts (consulting, meals, travel) and $0 in clinical research grants. Financial ties do not automatically imply conflict of interest, but are disclosed under the Sunshine Act.

Which pharmaceutical companies pay Dr. SULAIMAN ALHUMAID?

According to CMS Open Payments data, Dr. SULAIMAN ALHUMAID received funding from REGENERON HEALTHCARE SOLUTIONS ($488), GENENTECH USA ($251), and APELLIS PHARMACEUTICALS ($176).

Does Dr. SULAIMAN ALHUMAID receive research grants or speaking fees?

Dr. SULAIMAN ALHUMAID has received $1,256 in general promotional payments (such as consulting honoraria, meals, and speaking fees) and $0 in clinical research grants.

DR. SULAIMAN ALHUMAID

MDReal-Time Hydrated

Specialty: Ophthalmology, Retina Specialist

Practice Location: NORTH MIAMI BEACH, FL 33162

NPI Number: 1235672585

LIFETIME INDUSTRY VALUE

$1,256

2021 – 2025 Cumulative

Conflict of Interest Analysis

Dr. ALHUMAID is a verified Ophthalmology, Retina Specialist practitioner based in NORTH MIAMI BEACH, FL.

Between 2021 and 2025, Dr. ALHUMAID had an overall industry promotional and research financial footprint of $1,256 as recorded in the federal CMS Open Payments database.

$1,256 was received in general payments, which include consultation fees, travel expenses, honoraria, and sponsored meals.
$0 was allocated to sponsored clinical trials and medical research activities.

Dr. ALHUMAID's primary funding source is REGENERON HEALTHCARE SOLUTIONS, which accounts for $488 (representing 38.9% of overall industry footprint).

Data coverage: 2021 – 2025 · Source: CMS Open Payments · CMS publishes each year's data around June 30 of the following year.

Payout Trend Over Time

General Payments

Research Funding

Top Funding Entities

Pharmaceutical & Device Manufacturers making direct payments

REGENERON HEALTHCARE SOLUTIONS

Rank 1

$488

38.9%

GENENTECH USA

Rank 2

$251

20%

APELLIS PHARMACEUTICALS

Rank 3

$176

14%

Itemized Transaction Archives

Direct live query to Socrata CMS Open Payments API (Bypasses local DB)

Year:

2025

Filter < $250

Click "Load Live Logs" to query the federal Open Payments registry directly.

Frequently Asked Questions

Answers compiled using federal transparency disclosure records under the Sunshine Act.